The effect of long-term antipsychotic treatment on prolactin

Journal of Child and Adolescent Psychopharmacology

Volumn 16, Issue 3, 2006, Pages 317-326

  Staller, Jud ^a,b  

^a SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

^b State University of New York Upstate Medical University: College of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; CENTRAL STIMULANT AGENT; NEUROLEPTIC AGENT; OLANZAPINE; PROLACTIN; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR;

ADOLESCENT; ANXIETY DISORDER; ARTICLE; ATTENTION DEFICIT DISORDER; BIPOLAR DISORDER; BREAST DISEASE; CHILD PSYCHIATRY; CONTROLLED STUDY; DEMOGRAPHY; DEPRESSION; DIET RESTRICTION; DISRUPTIVE BEHAVIOR; DOSE RESPONSE; DRUG EFFECT; FEMALE; HUMAN; HYPERPROLACTINEMIA; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MENSTRUATION DISORDER; OUTPATIENT; PROLACTIN BLOOD LEVEL; PSYCHOPHARMACOTHERAPY; RISK ASSESSMENT; SCHIZOPHRENIA; SEXUAL DYSFUNCTION; TREATMENT DURATION;

ADOLESCENT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CHILD; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; DIBENZOTHIAZEPINES; FEMALE; HUMANS; MALE; MENTAL DISORDERS; PROLACTIN; RISPERIDONE;

EID: 33745145477     PISSN: 10445463     EISSN: None     Source Type: Journal    
DOI: 10.1089/cap.2006.16.317     Document Type: Article

References (56)

1. Alvarez-Tutor E, Forga-LLenas L, Rodriguez-Erdozain R, Goni-Iriarte MJ, Mendendez-Torre E, Alvarez-Tutor J: Persistent increase of PRL after oral contraceptive treatment. Alterations in dopaminergic regulation as possible etiology. Arch Gynecol Obstet 263:45-50, 1999.
2. Ananth J, Parameswaran S, Gunatilake S: Side effects of atypical antipsychotic drugs. Curr Pharm Des 10:2219-2229, 2004.
3. Ataya K, Mercado A, Kartaginer J, Abbasi A, Moghissi KS: Bone density and reproductive hormones in patients with neuroleptic induced hyperprolactinemia. Fertil Steril 50:876-880, 1988.
4. Alfaro CL, Wudarsky M, Nicolson R, Gochman P, Sporn A, Lenane M, Rapoport JL: Correlation of antipsychotic and prolactin concentrations in children and adolescents acutely treated with haloperidol, clozapine, or olanzapine. J Child Adolesc Psychopharmacol 12:83-91, 2002.
5. Baptista T, Molina MG, Martinez JL, de Quijada M, Calanche de Cuesta I, Acosta A, Paez X, Martinez JM, Hernandez L: Effects of the antipsychotic drug sulpiride on reproductive hormones in healthy premenopausal women: Relationship with body weight regulation. Pharmacopsychiatry 30:256-262, 1997.
6. Baptista T, Reyes D, Hernandez L: Antipsychotic drugs and reproductive hormones: Relationship to body weight regulation. Pharmacol Biochem Behav 62:409-417, 1999.
7. Basturk M, Karaaslan F, Esel E, Sofuoglu S, Tutus A, Yabanoglu I: Effects of short- and long-term lithium treatment on serum prolactin levels in patients with bipolar affective disorder. Prog Neuropsychopharmacol Biol Psychiatry 25:315-322, 2001.
8. Biller BM: Diagnostic evaluation of hyperprolactinemia. J Reprod Med 44:1095-1099, 1999.
9. Colao A, Loche S, Cappa M, Di Sarno A, Landi ML, Sarnacchiaro F, Facciolli G, Lombardi G: Prolactinomas in children and adolescents. Clinical presentation and long-term follow-up. J Clin Endocrinol Metab 83:2777-2780, 1998.
10. Conner P, Fried G: Hyperprolactinemia: Etiology, diagnosis, and treatment alternatives. Acta Obstet Gynecol Scand 77:249-262, 1998.
11. Conran MJ, Kearney PJ, Callaghan MN, Murphy D, Goggin T: Hypothalamic pituitary function testing on children receiving carbamazepine or sodium valproate. Epilepsia 26:585-588, 1985.
12. Dickson RA, Glazer WM: Hyperprolactinemia and sexual dysfunction. J Clin Psychiatry 60:125, 1999.
13. Dickson RA, Seeman MV, Corenblum B: Hormonal side effects in women: Typical versus atypical antipsychotic treatment. J Clin Psychiatry: 61(Suppl 3):10-15, 2000.
14. Findling RL, Aman MG, Eerdekens M, Derivan A, Lyons B: Long-term, open-label study of risperidone in children with severe disruptive behaviors and below-average IQ. Am J Psychiatry 161:677-684, 2004.
15. Findling RL, Kusumakar V, Daneman D, Moshang T, De Smedt G, Binder C: Prolactin levels during long-term risperidone treatment in children and adolescents. J Clin Psychiatry 64:1362-1369, 2003.
16. Glick I, Murray S, Vasudevan P, Marder S, Hu R: Treatment with atypical antipsychotics: New indications and new populations. J Psychiatr Res 35:187-191, 2001.
17. Halbreich U, Rojansky N, Palter S, Hreshchyshyn M, Kreeger J, Bakhai Y, Rosan R: Decreased bone mineral density in medicated psychiatric patients. Psychosom Med 57:485-491, 1995.
18. Hardan A, Johnson K, Johnson C, Hrecznyj: Case study: Risperidone treatment of children and adolescents with developmental disorders. J Am Acad Child Adolesc Psychiatry 35:1551-1556, 1996.
19. Hestnes A, Stovner LJ, Husoy O, Foiling I, Fougner KJ, Sjaastad O: Hormonal and biochemical disturbances in Down's syndrome. J Ment Defic Res 35(Pt3):179-193, 1991.
20. Hubinont CJ, Balasse H, Dufrane SP, Leclercq-Meyer V, Sugar J, Schwers J, Malaisse WJ: Changes in pancreatic B-cell function during late pregnancy, early lactation, and postlactation. Gynecol Obstet Invest 25:89-95, 1988.
21. Kartaginer J, Ataya K, Mercado A, Abbasi A: Osteoporosis associated with neuroleptic treatment: A case report. J Repro Med 35:198-202, 1990.
22. Kumari TM, Govindarajulu P: Hyperglycemic effect of prolactin in anterior pituitary transplanted rats. Encodrinol Jpn 37:819-825, 1990.
23. Linnolia M, Viukari M, Vaisanen K, Auvinen J: Plasma neuroleptic and prolactin levels in mentally retarded patients. Acta Pharmacol Toxicol (Copenhagen) 46:159-160, 1980.
24. Luciano AA: Clinical presentation of hyperprolactinemia. J Reprod Med 44(Suppl 12):1085-1090, 1999.
25. Lurie S, O'Quinn A: Neuroendocrine responses to methylphenidate and d-amphetamine: applications to attention-deficit disorder. J Neuropsych Clin Neurosci 3:41-50, 1991.
26. Lyons JS, MacIntyre JC, Lee ME, Carpinello S, Zuber MP, Fazio ML: Psychotropic medications prescribing patterns for children and adolescents in New York's public mental health system. Comm Ment Health J 40:101-118, 2004.
27. Masi G, Cosenza A, Mucci M: Prolactin levels in young children with pervasive developmental disorders during risperidone treatment. J Child Adolesc Psychopharmacol 11:389-394, 2001.
28. Masi G, Cosenza A, Mucci M, Brovedani P: A 3-year naturalistic study of 53 preschool children with pervasive developmental disorders treated with risperidone. J Clin Psychiatry 64:1039-1047, 2003.
29. McConville BJ, Arvanitis LA, Thyrum PT, Yeh C, Wilkinson LA, Chaney RO, Foster KD, Sorter MT, Friedman LM, Brown KL, Heubi JE: Pharmacokinetics, tolerability, and clinical effectiveness of quetiapine fumarate: An open-label trial in adolescents with psychotic disorders. J Clin Psychiatry 61:252-260, 2000.
30. Meltzer HY, Piyakalmala S, Schyve P, Fang VS: Lack of effect of tricyclic antidepressants on serum prolactin levels. Psychopharmacology (Berlin) 51:185-187, 1977.
31. Merino G, Carranza-Lira S, Martinez-Chequer JC, Barahona E, Moran C, Bermudez JA: Hyperprolactinemia in men with asthenozoospermia, oligozoospermia, or azoospermia. Arch Adnrol 38:201-206, 1997.
32. Mokrani M, Duval F, Diep TS, Bailey PE, Macher JP: Multihormonal responses to clonidine in patients with affective and psychotic symptoms. Psychoneuroendocrinology 25:741-752, 2000.
33. Monteleone P, Zontini G, Steardo L: Failure of the GABAergic drug, sodium valproate, to reduce basal plasma prolactin secretion in chronic schizophrenia. Psychoneuroendocrinology 10:475-480, 1985.
34. Patel NC, Sanchez RJ, Johnsrud MT, Crismon ML: Trends in antipsychotic use in a Texas medicaid population of children and adolescents: 1996-2000. J Child Adolesc Psychopharmacol 12:221-229, 2002.
35. Raap DK, Van de Kar LD: Selective serotonin reuptake inhibitors and neuroendocrine function. Life Sci 65:1217-1235, 1999.
36. Reavley A, Fisher AD, Owen D, Creed FH, Davis JR: Psychological distress in patients with hyperprolactinaemia. Clin Endocrinol (Oxford) 47:343-348, 1997.
37. Reyniak JV, Wenof M, Aubert JM, Stangel JJ: Incidence of hyperprolactinemia during oral contraceptive therapy. Obstet Gynecol 55:8-11, 1980.
38. Reis FM, Reis AM, Coimbra CC: Effects of hyperprolactinaemia on glucose tolerance and insulin release in male and female rats. J Endocrinol 153:423-428, 1997.
39. Saito E, Correll CU, Gallelli K, McMeniman M, Parikh UH, Malhotra AK, Kafantaris V: A prospective study of hyperprolactinemia in children and adolescents treated with atypical antipsychotic agents. J Child Adolesc Psychopharmacol 14:350-358, 2004.
40. Sarnacchiaro F, Colao A, Merola B, Di Sarno A, Landi ML, Di Somma C, Ferone D, Tolino A, Lombardi G: Different sensitivity to sodium valproate in healthy, nontumoral and tumoral hyperprolactinemic subjects. J Endocrinol Invest 20:513-518, 1997.
41. Schur S, Sikich L, Findling R, Malone R, Crimson M, et al.: Treatment recommendations for the use of antipsychotics for aggressive youth (TRAAY). Part I. A review. J Am Acad Child Adolesc Psychiatry 42:132-144, 2003.
42. Shaw JA, Lewis JE, Pascal S, Sharma RK, Rodriguez RA, Guillen R, Pupo-Guillen M: A study of quetiapine: Efficacy and tolerability in psychotic adolescents. J Child Adolesc Psychopharmacol 11:415-424, 2001.
43. Siklosi G, Bakos L, Csomor S, Jr, Marcsek Z, Olajos F: Episodic secretion of hormones and the diagnostic value of single blood estimates. I. LH, FSH, prolactin. Acta Med Hung 41:195-202, 1984.
44. Slattum PW, Venitz J, Barr WH: Comparison of methods for the assessment of central nervous system stimulant response after dextroamphetamine administration to healthy male volunteers. J Clin Pharmacol 36:1039-1050, 1996.
45. Sobrinho LG: Emotional aspects of hyperprolactinemia. Psychother Psychosom 67:w133-139, 1998.
46. Staller JA, Wade MJ, Baker M: Current prescribing patterns in outpatient child and adolescent psychiatric practice in central new york. J Child Adolesc Psychopharmacol 15:57-61, 2005.
47. Storch D: Gynecomastia with antipsychotics. J Am Child Adolesc Psychiatry 36:161, 1997.
48. Strickland JL, Wall JW: Abnormal uterine bleeding in adolescents. Obstet Gynecol Clin North Am 30:321-335, 2003.
49. Styne DM: Puberty and its disorders in boys. Endocrinol Metab Clin North Am 20:43-69, 1991.
50. Turgay A, Binder C, Snyder R, Fisman S: Long-term safety and efficacy of risperidone for the treatment of disruptive behavior disorders in children with subaverage IQ. Pediatrics 110:e34, 2002.
51. Weiden PJ, Miller AL: Which side effects really matter? Screening for common and distressing side effects of antipsychotic medications. J Psychiatr Prac 7:41-72, 2001.
52. Weizman R, Dick J, Gil-Ad I, Weitz R, Tyano S, Laron Z: Effects of acute and chronic methylphenidate administration on beta-endorphin, growth hormone, prolactin, and cortisol in children with attention-deficit disorder and hyperactivity. Life Sci 40:2247-2252, 1987.
53. Wieck A, Haddad PM: Antipsychotic-induced hyperprolactinaemia in women: Pathophysiology, severity, and consequences. Selective literature review. Br J Psychiatry 182:199-204, 2003.
54. Wudarsky M, Nicolson R, Hamburger SD, Spechler L, Gochman P, Bedwell J, Lenane MC, Rapoport JL: Elevated prolactin in pediatric patients on typical and atypical antipsychotics. J Child Adolesc Psychopharmacol 9:239-245, 1999.
55. Zaccaria M, Giordano G, Ragazzi E, Sicolo N, Foresta C, Scandellari C: Lack of effect of IM diazepam administration on hGH and hPRL secretion in normal and acromegalic subjects. J Endocrinol Invest 8:167-170, 1985.
56. Zito JM, Safer DJ, DosReis S, Gardner JF, Magder L, Soeken K, Boles M, Lynch F, Riddle MA: Psychotropic practice patterns for youth: A 10-year perspective. Arch Pediatr Adolesc Med 157:17-25, 2003.